Dear Reader,

I hesitated to even send you this.

After what I heard…

After who told me…

On January 7th… just outside Washington, D.C… I sat across from a man whose family has been tied to global power for decades.

Oil deals. Intelligence circles. Government insiders.

He leaned in and told me something that changed everything I thought I knew about the Iran war.

What you’re seeing on the news?

It’s not the real story.

Not even close.

The strikes… the chaos… the escalation…

It’s all part of something much bigger.

A global deal worth trillions.

And the only reason I know this is because of him — an anonymous contact who risked everything to pass this information along.

I verified it. Cross-checked it. Dug deeper.

And what I uncovered is something every American investor needs to see immediately.

Click here to see the full breakdown before it’s too late.

It’s a coordinated move that could reshape the global economy for decades.

But you need to see it for yourself.

Go here now and uncover the real reason behind the Iran war.

Regards,

Addison Wiggin

Founder, Grey Swan Investment Fraternity

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

By Thomas Hughes. Article Published: 7/16/2026.

Abbott Laboratories (NYSE: ABT) gave the market what it wanted in its Q2 earnings report, affirming that its acquisition of Exact Sciences was a sound decision. The critical takeaways are that comparable growth remains solid, the Exact Sciences business is gaining traction, and the near-term margin pressure from the acquisition is less severe than expected.

Looking ahead, improving profitability metrics have supported stronger guidance and market sentiment, as well as a robust rebound in the share price.

The share price rebound will be an important factor in the second half of 2026. Abbott’s stock had become overly depressed relative to its historical valuation and capacity for capital returns, signaling a buying opportunity for investors.

The post-release surge not only confirms support at the existing lows but is also backed by MACD and stochastic signals, suggesting that a full reversal may be underway. The market appears to have misjudged the Exact Sciences deal by focusing too heavily on near-term margin pressure and execution risk rather than its long-term commercial impact on revenue, margins and earnings.

Abbott Laboratories’ Q2 Report a Balm for Frayed Investor Nerves

Abbott Laboratories' Q2 report is solid, with reported growth of 13% and organic growth of 4.8%. Strength was underpinned by Exact Sciences and the 42.3% increase in Diagnostic services it brought, along with an 8.4% increase in Established Pharmaceutical Products and a 7.9% increase in Medical Devices. Nutrition, one of the smaller segments, declined by 3.1%. Strength was evident both domestically and internationally.

Margin news was the catalyst. The company’s margins contracted, but less than expected, leaving gross margin, operating income and net income above analysts' forecasts. The critical takeaway is that adjusted earnings per share (EPS) of $1.31 exceeded expectations by 235 basis points, providing sufficient financial strength to reinvest in the business while continuing to return capital to shareholders.

Guidance is another catalyst for trading in the second half of the year. The company maintained its forecast for organic revenue growth but improved its earnings outlook by raising the midpoint and narrowing the range for full-year results. With momentum building and results expected to accelerate in the second half, the guidance is likely conservative, setting the stage for additional catalysts by year’s end.

Abbott’s Capital Return Outlook Improves

Abbott’s capital returns were never in serious danger, but the threat of margin compression and weaker cash flow was sufficient to weigh on sentiment. The takeaway from the Q2 release, however, is that those concerns were misplaced. Capital returns will continue, including the dividend and share buybacks, and buybacks may accelerate.

As it stands, Abbott is a Dividend King with nearly 55 consecutive increases to its credit, a manageable 70% payout ratio and buybacks that offset the impact of annual increases while building shareholder value. As of mid-July, the dividend yield is attractive at a historical high of approximately 2.8%, while Q2 buybacks reduced the share count by 0.45%.

Analysts and Institutional Trends Reveal Optimistic Support for ABT Shares

Analyst trends reflect the dividend’s safety and the deep-value opportunity presented this year. While price targets have moderated, the market overreacted and pushed the stock below the low end of the target range. Price targets suggest a floor near $90, with substantial upside to the consensus target. Valuation metrics suggest the upside could reach triple digits over time.

The likely outcome is that analysts' price targets begin to firm, increasing conviction in the consensus outlook and the potential for a full stock price recovery. Until then, institutional activity suggests that this group is limiting risk in 2026, owning more than 75% of the shares and buying on balance. Buying is broad-based and includes funds, mutual funds, public retirement accounts and private wealth managers.

Abbott’s risks center on legacy issues related to its baby formula business, competition in the MedTech sector and the integration of Exact Sciences. Integration risks now appear limited, given the Q2 release and guidance update, leaving competition and legacy issues as the primary hurdles. Abbott is mitigating competition through pipeline investment, with numerous positive developments reported this quarter. Legacy issues involve baby formula manufacturing processes, regulatory scrutiny and the unresolved legal matters they have created.

This year’s catalysts include the successful integration of Exact Sciences, the revenue and margin boost from Cologuard and the expansion of MedTech wearables. Libre Duo, the world’s first dual glucose/ketone monitoring system, received the EU’s CE Mark, enabling sales throughout the region. Pipeline news also includes advances in two critical cardiovascular devices. What the market gets wrong is that ABT isn’t merely a legacy healthcare company and bond proxy; it is an innovative MedTech company expanding margins while investing in growth.